

Covid antidote clinical trial nod to VINS Bio

SWATI.BHARADWAJ@TIMESGROUP.COM

Hyderabad:

Immunologicals player VINS Bioproducts Ltd on Monday said it has received approval from the Drugs Controller General of India (DCGI) for conducting clinical trials of its Covid-19 antidote VINCOV-19.

The phase I and II trials for VINCOV-19, developed in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), will be conducted on around 300 volunteers nationwide at three hospitals across the country. One hospital each will be selected in the north, south and in Mumbai in the west zone, VINS Bioproducts CEO Siddharth Daga told **TOI**.